Abstract
Background
Administrative data have shown a lower mortality in hospitalized patients with pulmonary
embolism and cancer who receive a vena cava filter. In the absence of a randomized
controlled trial of vena cava filters in such patients, further investigation is necessary.
Therefore, we performed this investigation using administrative data from a different
database than used previously, and we investigate patients hospitalized in more recent
years.
Methods
We analyzed administrative data from the Premier Healthcare Database, 2010-2014, in
patients hospitalized with pulmonary embolism and solid malignant tumors. Patients
were identified on the basis of International Classification of Disease, Ninth Revision,
Clinical Modification codes.
Results
Patients aged >60 years had a lower in-hospital all-cause mortality with vena cava
filters than those who did not have filters, 346 of 4648 (7.4%) compared with 2216
of 19,847 (11.2%) (P < .0001) (relative risk 0.67). Among patients aged >60 years who received an inferior
vena cava, all-cause mortality within 3 months was 704 of 4648 (15.1%), compared with
3444 of 19,847 (17.4%) among those who did not receive a filter (P < .0001) (relative risk 0.86).
Conclusion
Elderly patients with pulmonary embolism and cancer may be a special population in
whom inferior vena cava filters reduce in-hospital and 3-month all-cause mortality.
Further investigation is needed, particularly in younger patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Thrombosis and cancer.Semin Oncol. 2000; 27: 362-374
- Cancer and thrombosis.Haemostasis. 1994; 24: 128-131
- Incidence of venous thromboembolism in patients hospitalized with cancer.Am J Med. 2006; 119: 60-68
- Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.Thromb Haemost. 2017; 117: 57-65
- Case fatality rate with vena cava filters in hospitalized stable patients with cancer and pulmonary embolism.Am J Med. 2013; 126: 819-824
- Requiem for liberalizing indications for vena caval filters?.Circulation. 2016; 133: 1992-1994
- Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial.JAMA. 2015; 313: 1627-1635
- Case fatality rate with pulmonary embolectomy for acute pulmonary embolism.Am J Med. 2012; 125: 471-477
- Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism.Am J Med. 2012; 125: 478-484
- Statistical Power Analysis for the Behavioral Sciences.Lawrence Erlbaum Associates, Hillsdale, NJ1988: 181
- Antithrombotic therapy for VTE disease: chest guideline and expert panel report.Chest. 2016; 149: 315-352
- Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.BMJ. 2010; 340: b5087
Article info
Publication history
Published online: November 10, 2017
Footnotes
Funding: This investigation was supported by grant 2412.ll from the Blue Cross Blue Shield of Michigan Foundation.
Conflict of Interest: None.
Authorship: All authors had access to the data and participated in preparation of the manuscript.
Identification
Copyright
© 2018 Published by Elsevier Inc.
